Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 24 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Boutari, Chrysoula [Clear All Filters]
(2013).
Predictive value of the ankle brachial index in patients with acute ischemic stroke..
Vasa. 43(1), 55-61.
(2014). Erectile dysfunction in chronic kidney disease: From pathophysiology to management..
World J Nephrol. 4(3), 379-87.
(2015). Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome..
World J Gastroenterol. 21(25), 7860-8.
(2015). Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?.
Am J Hypertens. 29(5), 662.
(2016). Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?.
J Clin Hypertens (Greenwich). 18(10), 1073.
(2016). Current challenges in antihypertensive treatment in the elderly..
Pol Arch Med Wewn. 126(7-8), 540-51.
(2016). Depression in hypertensive patients: the role of comorbidities..
J Hypertens. 34(7), 1441.
(2016). Discontinuation of Antihypertensive Treatment in Elderly Patients and Cognitive Function..
JAMA Intern Med. 176(3), 409.
(2016). PATHWAY-2: spironolactone for resistant hypertension..
Lancet. 387(10026), 1371-1372.
(2016). Renin-Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?.
J Clin Hypertens (Greenwich). 18(8), 828.
(2016). Blood pressure and cardiovascular outcomes: a closer look..
Lancet. 389(10076), 1295-1296.
(2017). Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension..
Curr Vasc Pharmacol. 16(1), 10-14.
(2017). Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun..
Curr Pharm Des. 23(10), 1540-1550.
(2017). SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature..
Curr Pharm Des. 23(10), 1510-1521.
(2017). Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?.
J Neurol Neurosurg Psychiatry. 88(3), 249-253.
(2017).
(2018).
Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?.
Metabolism. 96, vi-xi.
(2019). Renovascular Hypertension: Novel Insights:.
Current Hypertension Reviews. 15,
(2019).
(2019). Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis..
Metabolism. 154203.
(2020). The effect of underweight on female and male reproduction..
Metabolism. 107, 154229.
(2020). Renovascular Hypertension: Novel Insights..
Curr Hypertens Rev. 16(1), 24-29.
(2020).
(2021).